Completed PHASE3 INTERVENTIONAL 4-arm NCT05800301

Management of Retinitis Pigmentosa Via Combination of Wharton's Jelly-derived Mesenchymal Stem Cells and Magnovision

Bioretina, Ankara University Technopolis

Sponsor: Ankara Universitesi Teknokent

Interventions Magnovision Wharton's jelly derived mesenchymal stemcells

Updated 4 times since 2023 Last updated: Mar 23, 2023 Started: Jan 1, 2019 Primary completion: Dec 31, 2021 Completion: Dec 31, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05800301, this PHASE3 trial focuses on Retinitis Pigmentosa and remains completed. Sponsored by Ankara Universitesi Teknokent, it has been updated 4 times since 2019, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
May 2023 — Jul 2024 [monthly]

Completed PHASE3

First recorded

Jan 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ankara Universitesi Teknokent

Data source: Ankara Universitesi Teknokent

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ankara, Turkey (Türkiye)